2026 ICD-10-CM Diagnosis Code D07.5Carcinoma in situ of prostate

ICD-10-CM CodesC00–D49D00-D09D07

ICD-10-CM D07.5
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

D07.5 is a billable ICD-10-CM diagnosis code for carcinoma in situ of prostate. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 715 through 716, 722 through 724. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Male reproductive system cancers - prostate.

Code Identity

ICD-10-CM Code
D07.5
Billable Status
Yes — Valid for Submission
Code Describes
Carcinoma in situ of prostate
Short Description
Carcinoma in situ of prostate
Same as the full description in the CMS dataset.
Parent Code
Carcinoma in situ of other and unspecified genital organs

Code Classification

ChapterC00–D49Neoplasms
SectionD00-D09In situ neoplasms
CategoryD07Carcinoma in situ of other and unspecified genital organs
This CodeD07.5Carcinoma in situ of prostate

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Carcinoma in situ of prostate
  • Carcinoma in situ of prostatic ducts
  • High grade prostatic intraepithelial neoplasia
  • Prostatic intraepithelial neoplasia
  • Prostatic intraepithelial neoplasia and adjacent atypia

Tabular List NotesGuidance

Coding notes and annotation back-references applicable to this code.

Inclusion Terms

  • Prostatic intraepithelial neoplasia III (PIN III)
  • Severe dysplasia of prostate

Type 1 Excludes

  • dysplasia mild moderate of prostate N42.3
  • prostatic intraepithelial neoplasia II PIN II N42.3

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

External Cause of Injuries IndexGuidance

References for this code in the External Cause of Injuries Index.

    • Dysplasia
      • prostate
        • severe
    • Neoplasia
      • intraepithelial (histologically confirmed)
        • prostate (histologically confirmed) (PIN)
          • grade III (severe dysplasia)

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NEO039
Male reproductive system cancers - prostate
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Prostatic Intraepithelial Neoplasia

    a premalignant change arising in the prostatic epithelium, regarded as the most important and most likely precursor of prostatic adenocarcinoma. the neoplasia takes the form of an intra-acinar or ductal proliferation of secretory cells with unequivocal nuclear anaplasia, which corresponds to nuclear grade 2 and 3 invasive prostate cancer.

Table of NeoplasmsClinical

Anatomical sites in the Table of Neoplasms that reference this code family.

SiteMalig.
Primary
Malig.
Secondary
Ca
in situ
BenignUncertainUnspec.
prostate (gland)C61C79.82D07.5D29.1D40.0D49.59

Patient EducationClinical

Prostate Cancer

Cancer is a disease in which cells in the body grow out of control. Prostate cancer begins in the cells of the prostate. The prostate is a gland in the male reproductive system. It lies just below the bladder. It makes fluid that is part of semen.

The full article covers:

  • What is prostate cancer?
  • What causes prostate cancer?
  • Who is more likely to develop prostate cancer?
  • What are the symptoms of prostate cancer?
  • What are prostate tests and how is prostate cancer diagnosed?
  • What are the treatments for prostate cancer?
  • Can prostate cancer be prevented?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert D07.5 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
233.4 Ca in situ prostate
Exact Match The mapping is direct, with no qualifiers.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About D07.5Overview

Is D07.5 (Carcinoma in situ of other and unspecified genital organs) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report carcinoma in situ of prostate on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does D07.5 group to?

When carcinoma in situ of prostate is the principal diagnosis on an inpatient stay, it groups to MS-DRG 715, 716, 722, 723, 724, with relative weights from 0.6117 to 2.2373 depending on complications. Higher weights mean higher Medicare reimbursement.

What is the ICD-9 equivalent of D07.5?

Under the General Equivalence Mappings, carcinoma in situ of prostate converts to ICD-9-CM 233.4 (ca in situ prostate). The mapping is a direct match.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.